Chemo-radiotherapy alone

DRUG2 trials

Sponsors

Sun Yat-sen University, Sohag University

Conditions

ChemotherapyNasopharyngeal CancerPD-1 TherapyRadiotherapyTriple-Negative Breast Cancer (TNBC)

Phase 3

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

RecruitingNCT04453826

Sun Yat-sen UniversityChemotherapy, Nasopharyngeal Cancer, PD-1 Therapy +1

Start: 2020-09-01End: 2028-09-30Target: 388Updated: 2020-09-28

Unknown Phase

Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer

CompletedNCT07714382

Sohag UniversityTriple-Negative Breast Cancer (TNBC)

Start: 2026-05-01End: 2026-07-01Updated: 2026-07-20

Related Papers

Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial

BMJ2026-02-10